Korean J Gastrointest Endosc.  2008 Sep;37(3):179-184.

Famotidine versus Pantoprazole for the Prevention of Delayed Bleeding and Healing of Iatrogenic Ulcers after Endoscopic Mucosal Resection

• Hwang HI
• Park CH
• Yum SM
• Lee S
• Lee WS
• Kim HS
• Choi SK
• Rew JS

Abstract

BACKGROUND/AIMS: Endoscopic mucosal resection (EMR) currently serves as the minimally invasive treatment of choice for early gastric cancer and premalignant lesions of the stomach. There have been few studies addressing whether a proton pump inhibitor or a histamine 2-receptor antagonist is the most effective treatment for iatrogenic ulcers after EMR. We compared the effectiveness of pantoprazole and famotidine in treating iatrogenic ulcers and preventing bleeding after EMR without endoscopic submucosal dissection.
METHODS
Between March 2006 and April 2007, we retrospectively analyzed the effect of famotidine (40 mg/day) and pantoprazole (40 mg/day) on the healing of iatrogenic ulcers and control of bleeding after EMR.
RESULTS
During the study period, 126 patients underwent EMR. Eighty-one received famotidine, and 45 received pantoprazole. The mean duration of drug therapy was 44 days in each group. The stages of ulcers at 1 to 3 months after EMR were mostly scar stage, and there was no specific difference between the groups. Delayed bleeding was seen after EMR in one patient (1.2%) from the famotidine group and in one patient (2.2%) from the pantoprazole group. There were no other major complications after EMR.
CONCLUSIONS
Famotidine was no different than pantoprazole in its effectiveness toward preventing delayed bleeding and promoting healing of iatrogenic ulcers after EMR.

Keyword

Endoscopic mucosal resection; Famotidine; Pantoprazole

MeSH Terms

2-Pyridinylmethylsulfinylbenzimidazoles
Cicatrix
Famotidine
Hemorrhage
Histamine
Humans
Proton Pumps
Retrospective Studies
Stomach
Stomach Neoplasms
Ulcer
2-Pyridinylmethylsulfinylbenzimidazoles
Famotidine
Histamine
Proton Pumps